Hot products 
-
Mouse Anti-C5AR1 Recombinant Antibody (R63) (CBMAB-C9553-LY)
-
Mouse Anti-CD24 Recombinant Antibody (SN3) (CBMAB-C1037-CQ)
-
Mouse Anti-CD19 Recombinant Antibody (CBXC-1224) (CBMAB-C1491-CQ)
-
Mouse Anti-CRYAB Recombinant Antibody (A4345) (CBMAB-A4345-YC)
-
Mouse Anti-ACTN4 Recombinant Antibody (V2-6075) (CBMAB-0020CQ)
-
Mouse Anti-CARD11 Recombinant Antibody (CBFYC-0811) (CBMAB-C0866-FY)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7697) (CBMAB-1869CQ)
-
Mouse Anti-CEMIP Recombinant Antibody (3C12) (CBMAB-K0296-LY)
-
Mouse Anti-ADRB2 Recombinant Antibody (V2-180026) (CBMAB-A1420-YC)
-
Mouse Anti-CD164 Recombinant Antibody (CBFYC-0077) (CBMAB-C0086-FY)
-
Mouse Anti-ATP1B1 Recombinant Antibody (E4) (CBMAB-0463-LY)
-
Mouse Anti-AKT1 (Phosphorylated S473) Recombinant Antibody (V2-505430) (PTM-CBMAB-0067LY)
-
Mouse Anti-AMACR Recombinant Antibody (CB34A) (CBMAB-CA034LY)
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Mouse Anti-CFL1 Recombinant Antibody (CBFYC-1771) (CBMAB-C1833-FY)
-
Mouse Anti-4-Hydroxynonenal Recombinant Antibody (V2-502280) (CBMAB-C1055-CN)
-
Rat Anti-ADGRE4 Recombinant Antibody (V2-160163) (CBMAB-F0011-CQ)
-
Mouse Anti-CGAS Recombinant Antibody (CBFYM-0995) (CBMAB-M1146-FY)
-
Mouse Anti-DMD Recombinant Antibody (D1190) (CBMAB-D1190-YC)
-
Mouse Anti-ASH1L Monoclonal Antibody (ASH5H03) (CBMAB-1372-YC)
Endometrial Cancer
Fig.1 Endometrial cancer
Endometrial cancer is a cancer originating from the endometrium, which is the lining of the womb and uterus. The first sign is most abnormal vaginal bleeding but not associated with menstrual periods. Other symptoms include pain with urination, pelvic pain or sexual intercourse. Endometrial cancer occurs overwhelmingly after menopause. About 40% of cases are related to obesity. Besides it is also associated with diabetes, excessive estrogen exposure and high blood pressure. Hereditary causes contribution to 2–10% of the endometrial cancer cases. The most common type of endometrial cancer is endometrioid carcinoma, which making up more than 80% of cases. The five-year survival rate for endometrial adenocarcinoma following appropriate treatment is around 80%. Prognostic markers, like Serum HE4 have been studied recently.
Loading...



